In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 5, 2000, Pages 685-689

  Tsurumaki, Youko ^a   Manda, Hinako ^a   Takei, Masaya ^a   Hosaka, Masaki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; JAPAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NEISSERIA GONORRHOEAE; NONHUMAN; POSTOPERATIVE INFECTION; RESPIRATORY SYSTEM; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT;

EID: 0034064574     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.5.685     Document Type: Article

References (10)

1. Jones, R. N. (1996). Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. American Journal of Medicine 100, Suppl. 6A, S3-12.
2. Ubukata, K., Asahi, Y., Okuzumi, K. & Konno, M. (1996). Incidence of penicillin-resistant Streptococcus pneumoniae in Japan. The working group for penicillin-resistant S. pneumoniae. Journal of Infection and Chemotherapy 1, 177-84.
3. Seki, H., Kasahara, Y., Ohta, K., Yachie, A., Saikawa, Y., Sumita, R. et al. (1999). Increasing prevalence of ampicillin-resistant, non-β-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 45, 15-21.
4. Jones, R. N., Beach, M. L., Pfaller, M. A. & Doern, G. V. (1998). Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Diagnostic Microbiology and Infectious Disease 32, 247-52.
5. Hosaka, M., Yasue, T., Fukuda, H., Tomizawa, H., Aoyama, H. & Hirai, K. (1992). In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents and Chemotherapy 36, 2108-17.
6. Wakabayashi, E. & Mitsuhashi, S. (1994). In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrobial Agents and Chemotherapy 38, 594-601.
7. Fukuda, H., Hori, S. & Hiramatsu, K. (1998). Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 42, 1917-22.
8. Kato, N., Kato, H., Tanaka-Bandoh, K., Watanabe, K. & Ueno, K. (1997). Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 40, 631-7.
9. Japan Society of Chemotherapy. (1981). Standard method of MIC determinations. Chemotherapy 29, 76-9.
10. Nakashima, M., Uematsu, T., Kosuge, K., Kusajima, H., Ooie, T., Masuda, Y. et al. (1995). Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents and Chemotherapy 39, 2635-40.